Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas

Sadako Nishimura, Hiroshi Tsuda, Kiyoshi Ito, Masashi Takano, Yoshito Terai, Toshiko Jobo, Junzo Kigawa, Toru Sugiyama, Nobuo Yaegashi, Daisuke Aoki

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: Epithelial ovarian cancer (EOC) can be classified into 5 major histological types. Among them, clear cell adenocarcinoma (CCC) has a poor response to chemotherapy and poor prognosis compared with other histological types. Previously, we reported that the hypoxia-inducible protein 2 (HIG2) gene might be a new biomarker for CCCs, based on its expression profile. In this study, we generated a polyclonal antiserum to HIG2 to explore the use of HIG2 as a predictive biomarker in EOC. In addition, HIG2 expression was evaluated in uterine endometrial and renal CCCs. Methods: Hypoxia-inducible protein 2 expression was analyzed by immunohistochemistry in formalin-fixed surgical samples from 254 EOC, 17 endometrial, and 29 renal CCC patients. Results: Hypoxia-inducible protein 2 is expressed in 175 of 254 ovarian cancer cases. Cytoplasmic HIG2 expression is significantly more frequent in ovarian CCC (83.1%) than in serous (54.9%, P = 0.0001), mucinous (40%, P = 0.00002), or endometrioid (58.1%, P = 0.003) adenocarcinoma. The chemoresponse rate was higher in 24 ovarian CCC patients with cytoplasmic HIG2 expression than in 6 CCC patients without HIG2 expression (62.5% [15/24] vs 0% [0/6], P = 0.02). In contrast, there was no relationship between nuclear HIG2 expression and chemoresponse. Cytoplasmic and nuclear HIG2 expressions are significantly more frequent in ovarian and uterine than renal CCC (P = 0.04). Conclusions: Hypoxia-inducible protein 2 may be used as a marker for early detection of ovarian CCCs or for prediction of response to chemotherapy, but HIG2 expression does not predict survival of patients with CCC.

Original languageEnglish
Pages (from-to)220-226
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume20
Issue number2
DOIs
Publication statusPublished - 2010 Feb

Fingerprint

Clear Cell Adenocarcinoma
Proteins
Renal Cell Carcinoma
Biomarkers
Drug Therapy
Hypoxia
Ovarian epithelial cancer
Ovarian Neoplasms
Formaldehyde
Immune Sera
Adenocarcinoma
Immunohistochemistry
Kidney
Survival

Keywords

  • Clear cell adenocarcinoma
  • Endometrium
  • Kidney
  • Ovary

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Medicine(all)

Cite this

Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. / Nishimura, Sadako; Tsuda, Hiroshi; Ito, Kiyoshi; Takano, Masashi; Terai, Yoshito; Jobo, Toshiko; Kigawa, Junzo; Sugiyama, Toru; Yaegashi, Nobuo; Aoki, Daisuke.

In: International Journal of Gynecological Cancer, Vol. 20, No. 2, 02.2010, p. 220-226.

Research output: Contribution to journalArticle

Nishimura, Sadako ; Tsuda, Hiroshi ; Ito, Kiyoshi ; Takano, Masashi ; Terai, Yoshito ; Jobo, Toshiko ; Kigawa, Junzo ; Sugiyama, Toru ; Yaegashi, Nobuo ; Aoki, Daisuke. / Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. In: International Journal of Gynecological Cancer. 2010 ; Vol. 20, No. 2. pp. 220-226.
@article{bf82be68fe224a5fbb6f4e04cb25d811,
title = "Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas",
abstract = "Objectives: Epithelial ovarian cancer (EOC) can be classified into 5 major histological types. Among them, clear cell adenocarcinoma (CCC) has a poor response to chemotherapy and poor prognosis compared with other histological types. Previously, we reported that the hypoxia-inducible protein 2 (HIG2) gene might be a new biomarker for CCCs, based on its expression profile. In this study, we generated a polyclonal antiserum to HIG2 to explore the use of HIG2 as a predictive biomarker in EOC. In addition, HIG2 expression was evaluated in uterine endometrial and renal CCCs. Methods: Hypoxia-inducible protein 2 expression was analyzed by immunohistochemistry in formalin-fixed surgical samples from 254 EOC, 17 endometrial, and 29 renal CCC patients. Results: Hypoxia-inducible protein 2 is expressed in 175 of 254 ovarian cancer cases. Cytoplasmic HIG2 expression is significantly more frequent in ovarian CCC (83.1{\%}) than in serous (54.9{\%}, P = 0.0001), mucinous (40{\%}, P = 0.00002), or endometrioid (58.1{\%}, P = 0.003) adenocarcinoma. The chemoresponse rate was higher in 24 ovarian CCC patients with cytoplasmic HIG2 expression than in 6 CCC patients without HIG2 expression (62.5{\%} [15/24] vs 0{\%} [0/6], P = 0.02). In contrast, there was no relationship between nuclear HIG2 expression and chemoresponse. Cytoplasmic and nuclear HIG2 expressions are significantly more frequent in ovarian and uterine than renal CCC (P = 0.04). Conclusions: Hypoxia-inducible protein 2 may be used as a marker for early detection of ovarian CCCs or for prediction of response to chemotherapy, but HIG2 expression does not predict survival of patients with CCC.",
keywords = "Clear cell adenocarcinoma, Endometrium, Kidney, Ovary",
author = "Sadako Nishimura and Hiroshi Tsuda and Kiyoshi Ito and Masashi Takano and Yoshito Terai and Toshiko Jobo and Junzo Kigawa and Toru Sugiyama and Nobuo Yaegashi and Daisuke Aoki",
year = "2010",
month = "2",
doi = "10.1111/IGC.0b013e3181ca1e16",
language = "English",
volume = "20",
pages = "220--226",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas

AU - Nishimura, Sadako

AU - Tsuda, Hiroshi

AU - Ito, Kiyoshi

AU - Takano, Masashi

AU - Terai, Yoshito

AU - Jobo, Toshiko

AU - Kigawa, Junzo

AU - Sugiyama, Toru

AU - Yaegashi, Nobuo

AU - Aoki, Daisuke

PY - 2010/2

Y1 - 2010/2

N2 - Objectives: Epithelial ovarian cancer (EOC) can be classified into 5 major histological types. Among them, clear cell adenocarcinoma (CCC) has a poor response to chemotherapy and poor prognosis compared with other histological types. Previously, we reported that the hypoxia-inducible protein 2 (HIG2) gene might be a new biomarker for CCCs, based on its expression profile. In this study, we generated a polyclonal antiserum to HIG2 to explore the use of HIG2 as a predictive biomarker in EOC. In addition, HIG2 expression was evaluated in uterine endometrial and renal CCCs. Methods: Hypoxia-inducible protein 2 expression was analyzed by immunohistochemistry in formalin-fixed surgical samples from 254 EOC, 17 endometrial, and 29 renal CCC patients. Results: Hypoxia-inducible protein 2 is expressed in 175 of 254 ovarian cancer cases. Cytoplasmic HIG2 expression is significantly more frequent in ovarian CCC (83.1%) than in serous (54.9%, P = 0.0001), mucinous (40%, P = 0.00002), or endometrioid (58.1%, P = 0.003) adenocarcinoma. The chemoresponse rate was higher in 24 ovarian CCC patients with cytoplasmic HIG2 expression than in 6 CCC patients without HIG2 expression (62.5% [15/24] vs 0% [0/6], P = 0.02). In contrast, there was no relationship between nuclear HIG2 expression and chemoresponse. Cytoplasmic and nuclear HIG2 expressions are significantly more frequent in ovarian and uterine than renal CCC (P = 0.04). Conclusions: Hypoxia-inducible protein 2 may be used as a marker for early detection of ovarian CCCs or for prediction of response to chemotherapy, but HIG2 expression does not predict survival of patients with CCC.

AB - Objectives: Epithelial ovarian cancer (EOC) can be classified into 5 major histological types. Among them, clear cell adenocarcinoma (CCC) has a poor response to chemotherapy and poor prognosis compared with other histological types. Previously, we reported that the hypoxia-inducible protein 2 (HIG2) gene might be a new biomarker for CCCs, based on its expression profile. In this study, we generated a polyclonal antiserum to HIG2 to explore the use of HIG2 as a predictive biomarker in EOC. In addition, HIG2 expression was evaluated in uterine endometrial and renal CCCs. Methods: Hypoxia-inducible protein 2 expression was analyzed by immunohistochemistry in formalin-fixed surgical samples from 254 EOC, 17 endometrial, and 29 renal CCC patients. Results: Hypoxia-inducible protein 2 is expressed in 175 of 254 ovarian cancer cases. Cytoplasmic HIG2 expression is significantly more frequent in ovarian CCC (83.1%) than in serous (54.9%, P = 0.0001), mucinous (40%, P = 0.00002), or endometrioid (58.1%, P = 0.003) adenocarcinoma. The chemoresponse rate was higher in 24 ovarian CCC patients with cytoplasmic HIG2 expression than in 6 CCC patients without HIG2 expression (62.5% [15/24] vs 0% [0/6], P = 0.02). In contrast, there was no relationship between nuclear HIG2 expression and chemoresponse. Cytoplasmic and nuclear HIG2 expressions are significantly more frequent in ovarian and uterine than renal CCC (P = 0.04). Conclusions: Hypoxia-inducible protein 2 may be used as a marker for early detection of ovarian CCCs or for prediction of response to chemotherapy, but HIG2 expression does not predict survival of patients with CCC.

KW - Clear cell adenocarcinoma

KW - Endometrium

KW - Kidney

KW - Ovary

UR - http://www.scopus.com/inward/record.url?scp=77951896571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951896571&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e3181ca1e16

DO - 10.1111/IGC.0b013e3181ca1e16

M3 - Article

VL - 20

SP - 220

EP - 226

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -